[
    {
        "molecule_name": "antibody or antigen-binding fragment",
        "protein_target_name": "human Dectin-1",
        "binding_metric": "EC50",
        "value": "<2nM",
        "unit": "nM",
        "raw_mentions": "In some embodiments, provided herein is an antibody or antigen-binding fragment thereof that binds to human Dectin- 1, wherein the antibody or fragment binds to human Dectin- 1 expressed on the surface of a cell with an EC50 of less than 2nM, less than InM, or less than 0.5nM."
    },
    {
        "molecule_name": "antibody or antigen-binding fragment",
        "protein_target_name": "human Dectin-1",
        "binding_metric": "EC50",
        "value": "<1nM",
        "unit": "nM",
        "raw_mentions": "In some embodiments, provided herein is an antibody or antigen-binding fragment thereof that binds to human Dectin- 1, wherein the antibody or fragment binds to human Dectin- 1 expressed on the surface of a cell with an EC50 of less than 2nM, less than InM, or less than 0.5nM."
    },
    {
        "molecule_name": "antibody or antigen-binding fragment",
        "protein_target_name": "human Dectin-1",
        "binding_metric": "EC50",
        "value": "<0.5nM",
        "unit": "nM",
        "raw_mentions": "In some embodiments, provided herein is an antibody or antigen-binding fragment thereof that binds to human Dectin- 1, wherein the antibody or fragment binds to human Dectin- 1 expressed on the surface of a cell with an EC50 of less than 2nM, less than InM, or less than 0.5nM."
    },
    {
        "molecule_name": "Anti-Dectin-l/anti-hCD70 bispecific",
        "protein_target_name": "Dectin-1, CD70",
        "binding_metric": "affinity",
        "value": "1.8",
        "unit": "nM",
        "raw_mentions": "Anti-Dectin-l/anti-hCD70 bispecific binds Dectin-1- or CD70-expressing cells with an affinity of 1.8 nM or 12.34 nM, respectively.\nFIG. 12B also depicts the EC50 concentration (nM) based on a non-linear regression fitting (bottom right)."
    },
    {
        "molecule_name": "Anti-Dectin-l/anti-hCD70 bispecific",
        "protein_target_name": "Dectin-1, CD70",
        "binding_metric": "affinity",
        "value": "12.34",
        "unit": "nM",
        "raw_mentions": "Anti-Dectin-l/anti-hCD70 bispecific binds Dectin-1- or CD70-expressing cells with an affinity of 1.8 nM or 12.34 nM, respectively.\nFIG. 12B also depicts the EC50 concentration (nM) based on a non-linear regression fitting (bottom right)."
    },
    {
        "molecule_name": "2M24 anti-Dectin-1 antibody",
        "protein_target_name": "Dectin-1",
        "binding_metric": "EC50",
        "value": "0.3",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe 2M24 anti-Dectin-1 antibody was superior to commercial antibodies tested in terms of affinity, exhibiting an EC50 of 0.3 nM.\nThe agonistic 15E2 and the 255931 commercial antibodies exhibited EC50 of 14 nM and 16 nM, respectively, in cynomolgus monkey monocytes.\nAs shown in FIGs. 3A-3B, the fully human 2M24 showed high affinity binding to Dectin- 1 in transfected HEK cells (EC50 = 1.6 nM) and human monocytes (EC50 = 0.7 nM)."
    },
    {
        "molecule_name": "2M24",
        "protein_target_name": "Dectin-1",
        "binding_metric": "EC50",
        "value": "1.6",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe 2M24 anti-Dectin-1 antibody was superior to commercial antibodies tested in terms of affinity, exhibiting an EC50 of 0.3 nM.\nThe agonistic 15E2 and the 255931 commercial antibodies exhibited EC50 of 14 nM and 16 nM, respectively, in cynomolgus monkey monocytes.\nAs shown in FIGs. 3A-3B, the fully human 2M24 showed high affinity binding to Dectin- 1 in transfected HEK cells (EC50 = 1.6 nM) and human monocytes (EC50 = 0.7 nM)."
    },
    {
        "molecule_name": "2M24",
        "protein_target_name": "Dectin-1",
        "binding_metric": "EC50",
        "value": "0.7",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe 2M24 anti-Dectin-1 antibody was superior to commercial antibodies tested in terms of affinity, exhibiting an EC50 of 0.3 nM.\nThe agonistic 15E2 and the 255931 commercial antibodies exhibited EC50 of 14 nM and 16 nM, respectively, in cynomolgus monkey monocytes.\nAs shown in FIGs. 3A-3B, the fully human 2M24 showed high affinity binding to Dectin- 1 in transfected HEK cells (EC50 = 1.6 nM) and human monocytes (EC50 = 0.7 nM)."
    },
    {
        "molecule_name": "2M24/anti-hCD70",
        "protein_target_name": "Dectin-1",
        "binding_metric": "EC50",
        "value": "1.8",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAs shown in FIG. 12B, binding studies on cells revealed that 2M24/anti-hCD70 bound to the HEK293 cell line expressing Dectin-1 with an EC50 of 1.8 nM and bound to CD70-positive renal carcinoma cell lines with an EC50 of 12.34 nM (A498 cells) or 11.62 nM (786-0 cells)."
    },
    {
        "molecule_name": "2M24/anti-hCD70",
        "protein_target_name": "CD70",
        "binding_metric": "EC50",
        "value": "12.34",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAs shown in FIG. 12B, binding studies on cells revealed that 2M24/anti-hCD70 bound to the HEK293 cell line expressing Dectin-1 with an EC50 of 1.8 nM and bound to CD70-positive renal carcinoma cell lines with an EC50 of 12.34 nM (A498 cells) or 11.62 nM (786-0 cells)."
    },
    {
        "molecule_name": "2M24/anti-hCD70",
        "protein_target_name": "CD70",
        "binding_metric": "EC50",
        "value": "11.62",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAs shown in FIG. 12B, binding studies on cells revealed that 2M24/anti-hCD70 bound to the HEK293 cell line expressing Dectin-1 with an EC50 of 1.8 nM and bound to CD70-positive renal carcinoma cell lines with an EC50 of 12.34 nM (A498 cells) or 11.62 nM (786-0 cells)."
    },
    {
        "molecule_name": "Fab 2M24-mSA fusion",
        "protein_target_name": "Dectin-1",
        "binding_metric": "EC50",
        "value": "1.45",
        "unit": "nM",
        "raw_mentions": "Here is the extracted sentence:\n\nAs shown in FIGs. 20A-20C, the Fab 2M24-mSA fusion showed high affinity binding (EC50 = 1.45 nM) to Dectin-1 expressing cells."
    },
    {
        "molecule_name": "rituximab",
        "protein_target_name": "CD19",
        "binding_metric": "EC50",
        "value": "0.014",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. In PBMCs from donor 83, the EC50 with respect to CD19 expression was 0.014nM for rituximab and 0.080nM for 2M24/CD20 hlgGl bispecific (FIG. 37A).\n2. In PBMCs from donor 84, the EC50 with respect to CD19 expression was 0.013nM for rituximab and 0.090nM for 2M24/CD20 hlgGl bispecific (FIG. 37B).\n3. The EC50 with respect to CD19 expression was 0.020nM for rituximab and 0.95nM for 2M24/CD20 hlgGl bispecific."
    },
    {
        "molecule_name": "2M24/CD20 hlgGl bispecific",
        "protein_target_name": "CD19",
        "binding_metric": "EC50",
        "value": "0.080",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. In PBMCs from donor 83, the EC50 with respect to CD19 expression was 0.014nM for rituximab and 0.080nM for 2M24/CD20 hlgGl bispecific (FIG. 37A).\n2. In PBMCs from donor 84, the EC50 with respect to CD19 expression was 0.013nM for rituximab and 0.090nM for 2M24/CD20 hlgGl bispecific (FIG. 37B).\n3. The EC50 with respect to CD19 expression was 0.020nM for rituximab and 0.95nM for 2M24/CD20 hlgGl bispecific."
    },
    {
        "molecule_name": "rituximab",
        "protein_target_name": "CD19",
        "binding_metric": "EC50",
        "value": "0.013",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. In PBMCs from donor 83, the EC50 with respect to CD19 expression was 0.014nM for rituximab and 0.080nM for 2M24/CD20 hlgGl bispecific (FIG. 37A).\n2. In PBMCs from donor 84, the EC50 with respect to CD19 expression was 0.013nM for rituximab and 0.090nM for 2M24/CD20 hlgGl bispecific (FIG. 37B).\n3. The EC50 with respect to CD19 expression was 0.020nM for rituximab and 0.95nM for 2M24/CD20 hlgGl bispecific."
    },
    {
        "molecule_name": "2M24/CD20 hlgGl bispecific",
        "protein_target_name": "CD19",
        "binding_metric": "EC50",
        "value": "0.090",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. In PBMCs from donor 83, the EC50 with respect to CD19 expression was 0.014nM for rituximab and 0.080nM for 2M24/CD20 hlgGl bispecific (FIG. 37A).\n2. In PBMCs from donor 84, the EC50 with respect to CD19 expression was 0.013nM for rituximab and 0.090nM for 2M24/CD20 hlgGl bispecific (FIG. 37B).\n3. The EC50 with respect to CD19 expression was 0.020nM for rituximab and 0.95nM for 2M24/CD20 hlgGl bispecific."
    },
    {
        "molecule_name": "rituximab",
        "protein_target_name": "CD19",
        "binding_metric": "EC50",
        "value": "0.020",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. In PBMCs from donor 83, the EC50 with respect to CD19 expression was 0.014nM for rituximab and 0.080nM for 2M24/CD20 hlgGl bispecific (FIG. 37A).\n2. In PBMCs from donor 84, the EC50 with respect to CD19 expression was 0.013nM for rituximab and 0.090nM for 2M24/CD20 hlgGl bispecific (FIG. 37B).\n3. The EC50 with respect to CD19 expression was 0.020nM for rituximab and 0.95nM for 2M24/CD20 hlgGl bispecific."
    },
    {
        "molecule_name": "2M24/CD20 hlgGl bispecific",
        "protein_target_name": "CD19",
        "binding_metric": "EC50",
        "value": "0.95",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. In PBMCs from donor 83, the EC50 with respect to CD19 expression was 0.014nM for rituximab and 0.080nM for 2M24/CD20 hlgGl bispecific (FIG. 37A).\n2. In PBMCs from donor 84, the EC50 with respect to CD19 expression was 0.013nM for rituximab and 0.090nM for 2M24/CD20 hlgGl bispecific (FIG. 37B).\n3. The EC50 with respect to CD19 expression was 0.020nM for rituximab and 0.95nM for 2M24/CD20 hlgGl bispecific."
    },
    {
        "molecule_name": "2M24/Trop-2 bispecific antibody",
        "protein_target_name": "Trop-2",
        "binding_metric": "EC50",
        "value": "sub-micromolar",
        "unit": null,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe secondary antibody (AF647 goat Anti-Human) was used for detection by flow cytometry. Binding EC50 was determined using four-parameter logistic (4PL) non-linear regression. \n Binding EC50 was determined using four-parameter logistic (4PL) non-linear regression. The results demonstrated that 2M24/Trop-2 bispecific antibody binds with variable sub-micromolar affinity to different Trop-2-expressing cell lines (FIGS. 55A-55D).\n Cancer cell lines (HeLa, SiHa, BxPC-3, and Capan-2) were incubated with serial dilutions of the 2M24/Trop-2 hlgGlbispecific antibody or an isotype control antibody as a single concentration (300 nM)."
    }
]